Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric Population

Inclusion Criteria: * Males and females 2-18 years of age * Is clinically indicated for MRCP of the pancreas based on clinical criteria * Scheduled for MRCP and therapeutic or diagnostic ERCP or surgery for the assessment of chronic pancreatitis or acute recurrent pancreatitis (Children with a single episode of pancreatitis will not be included) * Parent or legal guardian has been fully informed and has personally signed and dated the Written Informed Consent and Health Insurance Portability Accountability Act (HIPAA) provisions * Is a male, or is a female not of childbearing potential, or is a female of childbearing potential who is using effective contraception and has a negative serum pregnancy test on the same day, but prior to, study drug administration * Is able and willing to complete all study procedures specified in the protocol Exclusion Criteria: * Presence of a pancreatic stent * History of any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease which, in the opinion of the investigator, precludes study participation * History of sensitivity to any of the ingredients in the study drug * Pregnancy * Any contraindication to MRI procedure, including but not limited to implanted metal devices (e.g., pacemaker, aneurysm clips, cochlear implants)